It’s vital that we continue to drive the development of novel therapies, so that myeloma patients can benefit from the most important advances in cancer treatment. We do this by investing directly in early-stage biopharma companies with promising technologies and conducting clinical trials that evaluate novel treatment approaches.
This is the MMRF’s venture philanthropy subsidiary. It invests in promising companies with innovative clinical assets and technologies that could be transformative for myeloma patients.
The Myeloma Investment Fund® collaborates closely with its portfolio companies to help them advance their multiple myeloma programs and improve their probability of success. This evergreen fund is supported entirely by philanthropy; all financial returns are reinvested back into the fund until there is a cure for every patient.
The Multiple Myeloma Research Consortium® (MMRC®) is a collaborative network of leading myeloma treatment centers that conduct early-stage clinical trials to evaluate novel treatment strategies for patients. This collaborative network drives ambitious clinical studies that simply could not be done by any single institution given their size and complexity. We focus our efforts on advancing innovative treatment approaches in the highest areas of unmet clinical need for patients, including relapsed/refractory, high-risk newly diagnosed, and high-risk smoldering myeloma.
In late 2024, the MMRF launched the innovative Horizon Clinical Trials Program through our Multiple Myeloma Research Consortium (MMRC). We are enrolling patients into the relapsed/refractory trial (Horizon-1), with the high-risk/newly diagnosed trial set to begin in 2025.
Optimizing Treatment Options
The MMRF initiated the MMRC Horizon Clinical Trials Program to optimize treatments by maximizing response rates and quality of life, while minimizing side effects in patient populations with high unmet need for safe and effective treatments, beginning in patients with relapsed and refractory myeloma. Horizon, through its design and multi-institutional cooperation, is set up to rapidly answer important research questions for patients whose disease is not always responsive – or durably responsive to currently available treatments.
The adaptive trial design will test multiple therapies and offers key advantages over traditional trials, such as the flexibility to adjust the study plan as needed to develop more precise treatments.
The first arm of Horizon is enrolling patients and will evaluate the most effective dose and schedule of TECVAYLI (teclistamab), manufactured by Johnson & Johnson, to maximize response and minimize side effects.
Expanding Clinical Trial Eligibility
The MMRF is committed to making the HORIZON trials as accessible and inclusive as possible to be representative of the real-world U.S. patient population. Our initiatives include:
This groundbreaking initiative strives to transform the landscape of multiple myeloma treatment and lead to better quality of life for patients.
